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Abstract
The Birt–Hogg–Dube ´ (BHD) disease is a genetic cancer syndrome. The responsible gene, BHD, has been identified by
positional cloning and thought to be a novel tumor suppressor gene. BHD mutations cause many types of diseases
including renal cell carcinomas, fibrofolliculomas, spontaneous pneumothorax, lung cysts, and colonic polyps/cancers. By
combining Gateway Technology with the Ksp-Cre gene knockout system, we have developed a kidney-specific BHD
knockout mouse model. BHD
flox/flox/Ksp-Cre mice developed enlarged kidneys characterized by polycystic kidneys,
hyperplasia, and cystic renal cell carcinoma. The affected BHD
flox/flox/Ksp-Cre mice died of renal failure at approximate three
weeks of age, having blood urea nitrogen levels over tenfold higher than those of BHD
flox/+/Ksp-Cre and wild-type littermate
controls. We further demonstrated that these phenotypes were caused by inactivation of BHD and subsequent activation of
the mTOR pathway. Application of rapamycin, which inhibits mTOR activity, to the affected mice led to extended survival
and inhibited further progression of cystogenesis. These results provide a correlation of kidney-targeted gene inactivation
with renal carcinoma, and they suggest that the BHD product FLCN, functioning as a cyst and tumor suppressor, like other
hamartoma syndrome–related proteins such as PTEN, LKB1, and TSC1/2, is a component of the mTOR pathway, constituting
a novel FLCN-mTOR signaling branch that regulates cell growth/proliferation.
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Introduction
Birt–Hogg–Dube ´ (BHD) syndrome is an autosomal dominant
genetic disease characterized by fibrofolliculomas (follicular ham-
artomas), renal cell carcinomas, spontaneous pneumothorax, and
lung cysts[1]. Renal cysts were also observed in some patients[2,3].
The BHD gene (accession number, BC015687), located on
chromosome 17p11.2, contains 14 exons spanning approximately
20 kb of genomic DNA and encodes a protein of 579 amino acids,
folliculin (FLCN) that has no known functional domains [4,5,6].
Germ-line mutations, somatic alterations, and loss of BHD mRNA
have been observed in patients with BHD, colorectal cancer, and in
some cases of gastric cancer; thus, BHD may be viewed as a
candidate tumor-suppressor gene[7,8,9,10].Germ-line mutations of
the counterpart BHD have also been identified in dogs and rats
having renal cell carcinomas and renal multiple cysts [11,12,13].
As one of the hamartoma syndromes, BHD shares many clinical
features (such as follicular hamartomas, mucosal fibromas, and
internal malignancy) with Cowden syndrome (CD, affected gene
PTEN), Peutz-Jeghers syndrome (PJS, affected gene LKB1), and
tuberous sclerosis complex (affected genes TSC1/TSC2) [14,15,16].
Of these, Cowden syndrome shares the most clinical features with
BHD. While PTEN, LKB1, and TSC1/2 are critical members of
the mTOR pathway [17], the BHD protein FLCN has also been
suggested to be involved [18,19]. These findings imply that FLCN,
like PTEN, may also be a pivotal tumor suppressor gene and a
potential playerin mTOR pathway. Over the last fewyears, interest
in FLCN has grown significantly. A few model organisms have been
used to explore the physiological role of FLCN. However, these
studies presented discrepant results, which leave the function of
FLCN elusive. In Drosophila, the Bhd homologue was linked to JAK-
STAT and Dpp pathway[20]. An in vitro experiment revealed that
FLCN interacts with AMPK in mammalian cell lines, associating
FLCN with the mTOR pathway[18], whereas in fission yeast, Bhd
was reported to activate the mTOR counterpart Tor2, presenting
an opposite role to Tsc1/2[19].
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replicate the complex processes of tumorigenesis in humans, the
development of BHD-deficient animal models will shed light on the
role of BHD in vivo and on the BHD-related biochemical pathways
responsible for neoplasia, which eventually could lead to the
development of therapeutic agents against BHD-related diseases.
Although natural mutants could be used for experimental models,
the possibilities of homozygous embryonic lethality and additional
unknown genetic changes often impede further analysis of the
phenotypes and the physiological role of the gene. The genetically
engineered conditional knockout mouse model can bypass this
barrier and provide a ‘‘cleaner’’ and more versatile system for
functional studies of BHD gene protein FLCN. While it might be a
suppressor of mouse cystogenesis demonstrated by a recent
study[21], BHD is expected to be a potential tumor suppressor
gene whosemutations have led to renal tumors and other diseases in
BHD patients. Therefore, it is essential to further elucidate whether
kidney-specific knockout of BHD in the mouse is also implicated in
kidney tumorigenesis, and what mechanism is involved.
Results
Generation of BHD conditional knockout construct and
mice
To generate a conditional knockout construct, we adopted the
MultiSite GatewayH Three-Fragment Vector Construction system
(Invitrogen, Carlsbad, CA) to inactivate the BHD gene by deleting
exons 3 and 4 (Figure 1A). The construct was electroporated into
129/Sv strain embryonic stem (ES) cells. Correctly targeted ES
cell clones were obtained after being selected with G418, screened
by long-range PCR, and confirmed using PCR and Southern blot
analysis (Figure 1B–E). For the generation of chimeras, ES cells
heterozygous for the BHD-floxed allele were injected into C57BL/
6 blastocysts by standard procedures. Chimeras were bred to
C57BL/6 mice to produce BHD
flox/+ heterozygotes, and germ-line
offspring were identified by PCR genotyping (Figure 1C).
BHD null mice are embryonic lethal
To determine whether ablation of BHD affected the viability of
mice, we first generated a conventional BHD-deficient mouse
model by intercrossing BHD
flox/flox mice with CMV-Cre transgenic
strains that express Cre recombinase in all tissues. While most
heterozygous BHD
+/2/CMV-Cre mice showed no obvious abnor-
malities at age of 18 months, the homozygous mutation was
embryonic lethal and BHD
2/2 mutants died between 3.5 dpc and
8.5 dpc, underscoring the importance of BHD in development.
Indeed, genes that are important in embryonic development are
frequently found to be the culprits in human cancers.
Kidney-specific inactivation of bhd results in renal cysts
BHD patients have a strong predisposition to develop bilateral
and multifocal renal tumors with a variety of histologies [22],
implying an effect of BHD on kidney tumorigenesis. We thus
generated a kidney-specific knockout by breeding BHD
flox/flox mice
to Ksp-Cre transgenic mice with expression of Cre-recombinase
under the control of the kidney-specific cadherin promoter [23].
While the BHD
flox/+/Ksp-Cre heterozygous mice showed a normal
phenotype at the age of 18 months, the homozygous BHD
flox/flox/
Ksp-Cre mice developed bilateral polycystic kidneys that were over
tenfold heavier than those of BHD
flox/+/Ksp-Cre and wild-type
littermate controls (Figure 2A,B). The BHD
flox/flox/Ksp-Cre mice
died of kidney failure at the age of 3 weeks, having over 10 times
higher levels of blood urea nitrogen (BUN) than normal littermate
controls (Figure 2C). The considerably low levels of BHD mRNA
detected by real time RT-PCR demonstrated inactivation of BHD
in most of the kidney cells (Figure 2D). The appearance of the
cysts here is similar to that found in polycystic kidney disease
caused by mutated PKD genes (Figure 3A,B). Histopathological
examination of the BHD
flox/flox/Ksp-Cre kidneys revealed extremely
dilated renal tubules that predominantly originated from collecting
ducts due to high expression of Ksp-Cre recombinase. While some
proximal tubules were highly or moderately dilated, most of the
other proximal tubules remained relatively normal as a result of
extremely low expression levels of Ksp-cre recombinase
(Figure 3C–F). Atrophic, compressed glomeruli were also
observed, and degeneration, necrosis, and haemorrhage were
frequently observed in the late stages. These morphological
changes suggest that homozygous BHD inactivation in the kidney
may cause loss of growth control in tubular epithelial cells.
Kidney-specific inactivation of bhd produced renal cell
carcinoma (RCC)
We further examined whether BHD
flox/flox/K s p - c r emice develop
renal carcinomas along with the cysts. Weobserved that kidneys from
mice less than two weeks old predominately presented dilated tubules
and cysts, whereas mice more than 18 days old also developed
hyperplasia and renal cell carcinoma in their polycystic kidneys
(Figure 3G–J). Hyperplastic areas frequently exhibited as multiple
layers of epithelial cells along the inner surface of the tubules
(Figure 3G, H). Renal cell carcinoma, which presents as cystic
RCC, was frequently observed in the extremely enlarged kidneys.
Cystic RCC was first described in 1986 and more cases have been
reported since then [24,25,26,27,28,29,30,31,32]. Images of human
cystic RCC are also available in the webpathology website (http://
www.webpathology.com/image.asp?case=66&n=8; http://www.
webpathology.com/image.asp?case=66&n=9). The occurrence of
cystic RCC in the general population is 4 to 10%, or 1 to 2% of all
renal tumors. The cystic RCC does not present as a solid mass, but
rather as a unilocular or multilocular cystic mass that is composed of
cancer cells growing in the form of cysts that are distinct from regular
cysts (Figures 3I,J and S1). While some of the tumor cells lined the
septa, the others protruded into the cystic lumen. Most of the tumor
cells were larger than the regular cystic cells. Binucleated cystic RCC
cells were also observed. Many cystic spaces are filled with
hemorrhage or proteinaceous fluid. No solid tumors were observed
in any of the affected mice, which may be attributed to their short
lifespan; three weeks might not be sufficient for solid tumor
development.
Deficiency of FLCN and subsequent activation of mTOR
contributed to renal cysts and RCCs
To elucidate the biochemical mechanisms of the cystogenesis and
carcinogenesis related to inactivation of the BHD gene, we
investigated the possible relevance of BHD to the mTOR signaling
pathwayforthefollowingreasons:1)ourmicroarrayanalysisrevealed
that ectopic expression of the BHD gene product, FLCN, led to
down-regulation of the AKT- related mTOR pathway signature
(Figure S2); 2) BHD, PTEN, LKB1,a n dTSC1/2 are all hamartoma
syndrome–related genes, and the roles of PTEN, LKB1, and TSC1/
2 in the mTOR pathway have been well-established; and 3) in vitro
experiments indicated that FLCN interacted with AMPK, a member
of the mTOR pathway [18]. All these clues implied that BHD gene
may play an important role in suppression of cystogenesis and
tumorigenesis and that its inactivation could lead to the formation of
renal cysts and RCC through the mTOR pathway.
Before investigating the correlation of FLCN with mTOR
pathway, we first examined the distribution of FLCN in normal
FLCN and Renal Cysts and RCC
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developed a human BHD monoclonal antibody that is compatible
with immunohistochemical analysis in the mouse. While FLCN was
predominantly expressed in the normal proximal tubules and
collecting ducts in the cortex, obvious expression was rarely
observed in the kidney distal tubules of mice at age of 3 weeks
(Figure 3K–N). In the polycystic kidney, FLCN was only detected
in relatively normal tubules (Figure 3C–F), which are mainly
proximal tubules. A small number of proximal tubules were also
enlarged due to moderate expression of Ksp-Cre recombinase
(Figure 3F, arrow), which is different from the previous report
where the proximal tubules are not involved. All the enlarged
tubules were FLCN-negative (Figure 3C,D), indicating a corre-
lation of the formation of cysts with inactivation of the BHD gene.
We then explored whether the inactivation of BHD resulted in
the activation of mTOR in affected cysts and RCCs. Immuno-
histochemical analysis showed that mTOR was activated through
phosphorylation in cysts and cystic RCCs (Figure 4A–C), which
stained FLCN-negative (Figure 4B). We further examined the
phosphorylation status of the downstream target S6 (Figure 4D).
Phosphorylated S6 has been observed in some cysts and in cystic
RCC. Although FLCN was reported to be a possible downstream
Figure 1. Targeting strategy and generation of BHD conditional knockout mice. (A) Construction of the BHD gene targeting vector using a
combination of the Gateway and loxp systems. A 3.5-kb 59 homology arm containing exon 2 and a 3.0-kb 39 arm carrying exons 5 and 6 were
integrated into the pDONR P4-P1R and pDONR P2R-P through a BP (attB and attP) reaction to generate the BHD-59 and BHD-39 homology entry
clones, respectively. A 1.3-kb fragment of genomic DNA bearing exons 3 and 4 of the BHD gene was inserted to the modified pDONR vector pENTR3C-
loxPMCS-loxP-FRT-neo-FRT between the SalI and NotI sites to generate a BHD-exon3-4-pENTR3C entry clone. The three entry clones, in combination
with the modified destination vector, were incubated to create a BHD-pDESTR4R3 targeting construct through BP recombination reaction. (B)
Positive-targeting ES clones were selected by long-range PCR and confirmed by Southern blot analysis. (C) PCR genotyping of mouse offspring using
tail DNA. (D, E) Knockout mice and normal controls were validated by Southern blot analysis.
doi:10.1371/journal.pone.0003581.g001
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that deficiency of FLCN activated mTOR pathway in vivo,
suggesting mTOR might a downstream target of FLCN. To
further elucidate the correlation of FLCN and mTOR, we applied
the mTOR inhibitor rapamycin to affected mice to see whether we
could inhibit or reverse the development of cysts. Rapamycin
treatment significantly extended the survival period of BHD
flox/flox/
Ksp-Cre mice and inhibited the development of cysts relative to
control mice; some mice survived more than 50 days. However,
once the rapamycin treatment was stopped, cysts redeveloped
rapidly and the mice died within 10 days. This result indicated that
rapamycin can inhibit cystic cell growth, but cannot reverse the
cystic kidney phenotype. We also tested a few other members of
the mTOR pathway (e.g. AKT) through IHC; no significant
changes were observed or inconsistent results were obtained
following inactivation of BHD, implying a novel FLCN-mTOR
pathway branch may exists. In addition, FLCN might be related to
other signaling pathways. Obviously, the precise in vivo mode of
action of FLCN merits more investigation.
Discussion
In this study, we provide the first evidence that the BHD protein
FLCN predominantly expresses in the proximal tubules and
collecting ducts of the renal cortex (Figure 3K–N). By developing
and subsequently analyzing the conditional BHD knockout mouse
model, we demonstrate that the deletion of BHD in the mouse
kidney leads to cystic renal cell carcinoma (cystic RCC) in addition
to polycystic kidney and hyperplasia. The cystic RCC was only
observed in the older affected mice ($20 days old). This implies
that most of the polycystic kidneys would only present regular cysts
and various extents of hyperplasia if the affected mice are
sacrificed earlier. Thus, although some kidney-specific knockout
animal models of RCC-related genes failed to develop
RCC[21,33,34], our data provide a connection between kidney-
specific BHD gene inactivation and renal carcinogenesis. This
finding suggests that BHD may act as a suppressor for both
cystogenesis and tumorigenesis.
No solid kidney tumors were observed in any of the affected
mice, which may be attributed to their short lifespan and mouse
distinct genetic background. It is entirely possible that if the cysts
had not caused kidney failure at age of three weeks, progression of
these cystic RCC to solid tumors would have occurred. In
addition, inactivation of BHD gene in the kidney causes a large
proportion of tubules to form cysts. Once cystogenesis starts, fast-
growing cysts become dominant and lead to highly cystic kidneys,
kidney failure, and early death. Thus, lack of appropriate
microenvironment might be another reason that the malignant/
Figure 2. Phenotypes of BHD
flox/flox/Ksp-Cre mice. (A) BHD
flox/flox/Ksp-Cre mice developed polycystic kidney and died at age of three
weeks. The kidneys from heterozygotes were phenotypically normal, similar to the ones from wild-type mice. (B) The organs from the affected mice
were normal except for the kidneys (10 days old). There was not much size difference between the normal control kidneys and the affected kidneys at
birth. However, the difference became apparent after the age of 5 days. At age of 10 days, the polycystic kidneys were approximate 15 times larger
than those from normal controls. (C) Biochemical analysis revealed that the conditional knockout mice died of kidney failure due to high level of
blood urea nitrogen (BUN). The BUN level dramatically elevated 15 days after birth. Most of the mice died at the age of 21 days. (D) The mRNA level of
BHD in the kidneys of BHD
flox/flox/Ksp-Cre mice is significantly lower than that in wild-type kidneys. The heterozygote also shows lower mRNA
expression relative to the wild type. m=month; d=day. f/f=flox/flox; f/+=flox/+.
doi:10.1371/journal.pone.0003581.g002
FLCN and Renal Cysts and RCC
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more complicated and slower process.
Our results further demonstrated that deficiency of BHD
product FLCN led to activation of mTOR pathway in cystic
cells, supporting the recent report and consolidating that FLCN is
involved in mTOR pathway and mTOR may be downstream
target of FLCN[21]. Interestingly, BHD is a member of the
hamartoma syndrome family that includes Cowden syndrome
(CD, affected gene PTEN), Peutz-Jeghers syndrome (PJS, affected
gene LKB1), and tuberous sclerosis complex (affected genes TSC1/
TSC2) [14,15,16]. While PTEN, LKB1, and TSC1/2 have played
pivotal roles in the mTOR pathway, our findings suggest that
BHD protein FLCN, like other hamartoma syndrome–related
proteins such as PTEN, LKB1, and TSC1/2, is an important
component of the mTOR pathway, constituting a novel FLCN-
mTOR signaling branch that regulates cell growth/proliferation,
though FLCN may involve in other pathways.
Materials and Methods
Design and generation of BHD conditional knockout
construct
The MultiSite GatewayH Three-Fragment Vector Construction
system (Invitrogen, Carlsbad, CA) was modified for the purpose of
fabricating recombination vectors [35]. Of the four vectors supplied
in the system, the pDONR vectors, pDONR P4-P1R, and pDONR
P2R-P3 were used to generate the 59 and 39 homology arm entry
clones. Another vector, pENTR3C, was used to carry a targeted
gene sequence of interest. To meet the gene targeting purpose, a
1.8-kb loxP-FRT-neo-FRT fragment excised from p-loxp-
2FRTPGKneo (a gift of D. Gordon) was added to generate
pENTR3CloxP-FRT-neo-FRT, which allowed later excision of
BHD exons 3 and 4 and the neomycin-resistance gene by cre-
mediated recombination in vivo. Synthetic oligonucleotides were
used to insert an additional loxP site into the DraI site of the
pENTR3C-loxPFRT-neo-FRT vector.OligonucleotidesloxPF (59-
ATAACTTCGTATAGCATACATTATACGAAGTTATTT-39)
and loxPR1 (59-AAATAACTTCGTATAATGTATGCTATAC-
GAAGTTAT-39) (IDT, Coralville, IA) were phosphorylated with
T4 polynucleotide kinase (Invitrogen), annealed, and inserted into
the DraI-digested pENTR3C-loxP-FRTneo-FRT vector to gener-
ate pENTR3C-loxPMCS-loxP-FRT-neo-FRT.
To enrich targeted ES cell clones, we inserted a TK-negative
selection cassette downstream of the attR3 site in the destination
vector. The attR4-ccdB-attR3 domain was amplified from the
pDEST/R4-R3 vector using the following primers: 59-GCCT-
CGAGCAGGAAACAGCTATGAC-39 and 59-GCCTCGAG-
TAAAACGACGGCCAGTG-39. After digestion by XhoI, this
domain was inserted into the XhoI site of the pPGKneo/TK vector
(a gift from T. Gridley).
Figure 3. Inactivation of FLCN in BHD
flox/flox/Ksp-Cre mice led to
polycystic disease, hyperplasia, cystic renal cell RCC. (A,B)
Deficiency of FLCN resulted in polycystic disease. (C, D) No FLCN
expression was detected in cysts (enlarged tubules). However, FLCN
was still expressed in relatively normal tubules where BHD was not
deleted or completely eliminated by Ksp-Cre due to no or low Ksp-Cre
expression in some proximal tubules. (E, F) Most of the relative normal
tubules were proximal tubules stained by proximal tubule-specific
marker lotus tetragonolobus lectin (LTL). Many of the proximal tubules
remained relatively normal, though some proximal tubules were also
enlarged (indicated by arrow. (G, H) Hyperplasia (indicated by arrow)
was frequently observed in the cysts. (I, J) Cystic renal cell carcinomas
were also one of the important consequences of kidney-targeted BHD
gene inactivation in BHD
flox/flox/Ksp-Cre mice, which is morphologically
distinct from regular cysts showed in A and B. (K, L) FLCN is
predominately expressed in proximal tubules, which was demonstrated
by the proximal-specific marker LTL (M). FLCN expression is quite weak
in distal tubules, which was marked by the distal-tubule-specific marker,
Na-Cl-cotransporter (TSC) (N). Scale bar=50 mm.
doi:10.1371/journal.pone.0003581.g003
FLCN and Renal Cysts and RCC
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homology arm containing exon 2 and a 3.0-kb 39 arm carrying
exons 5 and 6, PCR-amplified using Pfx polymerase (Invitrogen),
were integrated into the pDONR P4-P1R and pDONR P2R-P
through BP reaction (attB and attP sites) to generate the BHD-59
and BHD-39 homology entry clones, respectively. A 1.3-kb
fragment of genomic DNA bearing exons 3 and 4 of the BHD
gene was inserted into the modified pDONR vector pENTR3C-
loxPMCS-loxP-FRT-neo-FRT between the SalI and NotI sites to
generate a BHD-exon3-4-pENTR3C entry clone. Finally, the
three entry clones, in combination with the modified destination
vector, were incubated to create a BHD-pDESTR4R3 targeting
construct through BP recombination reaction.
Identification of homologous recombinant ES cells and
generation of kidney-specific knockout mice
The generated BHD-pDESTR4R3 targeting construct carries
an ampicillin-resistant gene and a neomycin-resistant gene flanked
by FRT sites. The construct was linearized with ScaI for
electroporation into 129/sj strain ES cells. After selection with
500 mg/ml G418 (Invitrogen), 1,039 ES cell clones were isolated.
The G418-positive ES clones were first screened by long-range
PCR and then confirmed by Southern blot analysis. For the
generation of chimeras, ES cells heterozygous for the BHD
flox/+
allele were injected into C57BL/6 blastocysts by standard
procedures. Chimeras were bred to C57BL/6 mice, and germline
offspring were identified by PCR genotyping. To remove the
neomycin gene flanked by two FTR sites, BHD
flox/+ mice were
crossed to FlpeR transgenic mice that express the site-specific
recombinase FLP (FLPe). Then, BHD
flox/+ heterozygous mice were
intercrossed to give rise to mice homozygous for the BHD
flox allele,
i.e., BHD
flox/flox mice.
To obtain mice with kidney-specific inactivation of BHD,
BHD
flox/flox mice were first bred to Ksp-Cre transgenic mice to
generate BHD heterozygous mice (BHD
flox/+/Ksp-Cre in kidneys).
BHD
flox/+/Ksp-CremicethenwerebackcrossedtoBHD
flox/flox miceto
generate BHD homozygous mice (BHD
flox/flox/Ksp-Cre in kidneys).
All mice were manipulated and housed according to protocols
approved by the Institutional Animal Care and Use Committee
(IACUC) of Van Andel Institute and conducted in an ethical,
humane, and scientifically justified manner, and in full compliance
with applicable regulations.
Genotyping, RNA and protein analysis
ES cell DNA and tail DNA was extracted by using automated
DNA isolation system (Kurabo Industries) and subjected to regular
PCR and long-range PCR genotyping analysis (see supplementary
Table S1 for PCR primers). For genotyping by Southern blot
analysis, DNA from ES cells or tissues was extracted using
standard DNA extraction procedure. Purified DNA was digested
by Xmn Io rHind III, isolated by 0.8% agarose gel, and transferred
onto nylon membrane. UV-linked or dried membranes were
subjected to DNA hybridization with 59 or 39 probes.
Total RNA was isolated from various mouse tissues and cystic
cell lines with Trizol reagent (Invitrogen) according to the
manufacturer’s instructions. Purified RNA was used for quantita-
tive analysis (real-time RT-PCR) through ABI Prism 7700
Sequences Detector (Applied Biosystems).
Figure 4. mTOR signaling pathway was activated in the cystic cells, cystic RCC cells. (A) Cystic RCC was stained by hematoxylin and eosin
(H&E). (B) No FLCN expression was detected in cystic RCC, indicating deletion of the BHD gene. Phosphorylated mTOR (C) and phosphorylated S6 (D)
staining was observed in the corresponding FLCN-deficient cells. Scale bar=50 mm.
doi:10.1371/journal.pone.0003581.g004
FLCN and Renal Cysts and RCC
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whole-cell extracts prepared by homogenization were lysed in 1%
Nonidet P-40, 50 mM Tris (pH 7.4), 150 mM NaCl, 1 mM
EDTA, and 15% glycerol, plus standard protease inhibitors
(protease inhibitor cocktail tablets, Roche Diagnostics). Equal
amounts of mutant and control kidney cell protein extracts were
size-separated by 10% SDS-PAGE and transferred to PVDF
membranes (Invitrogen). FLCN was detected with a mouse
monoclonal anti-FLCN antibody (developed by Laboratory of
Antibody Technology) at a dilution of 1:750 using the enhanced
chemiluminescence detection system.
Immunohistochemistry and tubular marker staining
Immunohistochemical analysis was performed following the
manufactory’s protocols. The antibodies used include anti-FLCN
mAb, anti-Phospho-mTOR Rabbit mAb (Cell Signaling), anti-
Phospho-S6 Ribosomal Protein (Cell Signaling). Proximal tubules
were stained by biotinylated Lotus Tetragonolobus Lectin (LTL,
Vector Laboratories), and distal tubules were detected by using
rabbit anti-thiazide-sensitive NaCl contransporter affinity purified
polyclonal antibody (TSC, Chemicon) Tubular markers. Marker
biotinylated Peanut Agglutinin (PNA, Vector Laboratories) was
used to stain collecting ducts.
Phenotyping and histopathology
Newborn mice were monitored daily. Sick mice were
distinguished from healthy ones by enlarged abdomen at age of
10 days. Totally 73 BHD
flox/flox/Ksp-Cre mice and 55 normal
control littermates were collected for phenotyping and histopath-
ological analysis. Mouse body weight, kidney weight were
measured upon euthanasia by CO2 inhalation. Tissues including
kidneys, lung, liver, spleen, heart, stomach, intestine, brain, testes
were collected and fixed in 4% paraformaldehyde for 24 hours
and kept in 70% ethanol for 12 hours before paraffin block
preparation. Paraffin blocks were sectioned at 3 mm thick and
stained with hematoxylin and eosin (H&E). Stained slides were
evaluated by a board-certified veterinary pathologist B. Sigler and
pathologists X. Yang and J. Peng.
Blood biochemical analysis
Mouseblood was collected by cardiac puncture at age of 5 days, 10
days, and 15 days, and 20 days. Serum was collected after
centrifugation and stored at 280uC for further biochemical analysis.
Rapamycin treatment of BHD
flox/flox/Ksp-Cre mice and
BHD
flox/+/Ksp-Cre and wild-type control littermates
Totally 29 mice from three litters were used for rapamycin
treatment (n=15) and control (n=14). Mice from each litter at
postnatal 7 days were randomly divided into two groups of
rapamycin treatment and control. Rapamycin (LC Laboratories,
Woburn, MA) was dissolved in ethanol at a concentration of
20 mg/mL and stored at 220uC. The rapamycin solution was
freshly prepared by diluting the rapamycin stock to 250 mg/ml in
buffer (1:1 10% PEG-400, 8% ethanol:10% Tween 80) and were
injected by intraperitoneally daily at a dose of 2.5 mg/kg body
weight for the duration of the treatment. Control animals received
i.p. injection of equal amount of vehicle (5% PEG-400, 4%
ethanol, and 5% Tween 80). Mice were treated for at least two
weeks starting at postnatal day 7. Moribund mice were subjected
to CO2 euthanasia, dissection, and analysis in the duration of the
treatment.
Supporting Information
Table S1 Primer used for BHD knockout genotyping
Found at: doi:10.1371/journal.pone.0003581.s001 (0.02 MB
XLS)
Figure S1 Additional cystic RCC samples stained by hematox-
ylin and eosin. Cystic spaces are filled with proteinaceous fluid (A–
J) or hemorrhage (K,L) in cystic RCC. The tumor cells have clear
cytoplasm and hyperchromatic nuclei lining the septa or growing
into the cystic lumina. Scale bar=50 mm.
Found at: doi:10.1371/journal.pone.0003581.s002 (5.38 MB TIF)
Figure S2 Microarray analysis revealed that ectopic expression
of FLCN led to down-regulation of the AKT- related mTOR
pathway signature.
Found at: doi:10.1371/journal.pone.0003581.s003 (0.29 MB TIF)
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